Home › Acute Lymphoblastic Leukemia › NCT04929899
Bright Ideas - CIN Feasibility Study
Improving Chemotherapy-induced Nausea Control Through Bright Ideas®-CIN Training: a Feasibility Study in Children Receiving Oral Chemotherapy
Who can join
Ages 4 to 18 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age: ≥ 4 years (PeNAT validated in patients 4 to 18 yrs) * newly diagnosed or recurrent disease: first diagnosis of ALL (i.e. non-relapsed) in maintenance therapy * English, French or Spanish-speaking with an English, French or Spanish-speaking guardian (PeNAT available in these languages) * without physical or cognitive impairments that preclude use of the PeNAT * planned to receive PO 6-mercaptopurine * not planned to receive IV, IM, SC or IT chemotherapy or oral or IV corticosteroids during the 7-day study period
About the study
In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.
What is being tested
- Bright Ideas - CIN Training (behavioral)
Sponsor: The Hospital for Sick Children · Participants: 75 · Started: Mar 1, 2022
Contact the study team
- Lee Dupuis, PhD · Phone: 416-813-7762
- Tadi Hondonga · Phone: 416-813-7654
Official record on ClinicalTrials.gov — NCT04929899
Locations in the U.S.
| California | Children's Hospital Los Angeles, Los Angeles |
| New Jersey | Rutgers Cancer Institute, New Brunswick |
| Virginia | Inova Children's Hospital, Falls Church |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.